Envíe este artículo por correo electrónico 
Papel de la podoplanina en focos de infección de cabeza y cuello en población adulta y pediátrica: Una revisión sistemática
Resumen
El carcinoma escamocelular de cabeza y cuello (CCECC) se considera un cáncer importante a nivel mundial, contribuyendo al aumento de la enfermedad y la mortalidad. Ocupa el sexto lugar entre los cánceres a nivel mundial, con más de 550.000 casos nuevos cada año. Material y métodos: Se exploraron importantes bases de datos como Medline mediante una búsqueda bibliográfica exhaustiva, lo que resultó en una revisión sistemática sobre la podoplanina. Resultados: Se identificaron catorce artículos científicos sobre podoplanina, fechados entre 2020 y 2024. Conclusiones: La podoplanina (PDPN) se ha convertido en un factor clave en el comportamiento y la progresión tumoral de diversos carcinomas. Estructuralmente única, la PDPN carece de dominios funcionales reconocibles, pero ejerce profundos efectos en el comportamiento celular a través de interacciones con diversas proteínas, orquestando procesos como la migración, la invasión y la metástasis de células tumorales. En esta revisión sistemática se analiza información detallada sobre la podoplanina y su papel vital en el campo de la patología oral y maxilofacial.
Palabras clave
Texto completo:
PDF (English)Referencias
Prasad B, Kashyap B, Babu GS, Kumar GR, Manyam R. Expression of Podoplanin in Different Grades of Oral Squamous Cell Carcinoma. Ann Med Health Sci Res. 2015; 5: 299–304. [Pubmed] [Google Scholar]
Kreppel M, Kreppel B, Drebber U,,Wedemayer I, Rothamel D, Zöller JE,,Scheer M. Podoplanin expression in oral,leukoplakia: prognostic value and
clinicopathological implications. Oral,Diseases. 2012; 18: 692–9. [Pubmed],[Google Scholar]
Mary Jibi A, Basavaraj V. Study of,Podoplanin Expression in Head and Neck,Squamous Cell Carcinoma. Iran J Pathol.,2022; 17: 275–84. [Pubmed] [Google,Scholar]
Sanderson RJ. Squamous cell carcinomas of the head and neck * Commentary: Head and neck carcinomas in the developing world. BMJ. 2002; 325:
–7. [Pubmed] [Google Scholar]
Zhang M, Zhang QS, Zheng HS, Wang XY, Feng SQ, Tian WJ, Fan HT. . Clinical, demographic and psychological characteristics of infertile male
smokers in Northeast China. J Int Med Res. 2016; 44: 75–80. [Pubmed] [Google Scholar]
Raica M, Cimpean AM, Ribatti D. The role of podoplanin in tumor progression and metastasis. Anticancer Res. 2008; 28: 2997-3006. [Pubmed] [Google Scholar]
Renart J, Carrasco-Ramírez P, Fernández-Muñoz B, Martín-Villar E, Montero L, Yurrita MM, Quintanilla M. New insights into the role of podoplanin in epithelial-mesenchymal transition. Int Rev Cell Mol Biol. 2015; 317: 185-239. [Pubmed] [Google Scholar]
Astarita JL, Acton SE, Turley SJ. Podoplanin: emerging functions in development, the immune system, and cancer. Front Immunol. 2012; 3: 283.
[Pubmed] [Google Scholar]
Wicki A, Lehembre F, Wick N, Hantusch B, Kerjaschki D, Christofori G. Tumor invasion in the absence of epithelialmesenchymal transition: podoplaninmediated remodeling of the actin cytoskeleton. Cancer Cell. 2006; 9: 261-72. [Pubmed] [Google Scholar]
Krishnan H, Rayes J, Miyashita T, Ishii G, Retzbach EP, Sheehan SA, Takemoto A, Chang YW, Yoneda K, Asai J, Jensen L, Chalise L, Natsume A, Goldberg GS. Podoplanin: An emerging cancer biomarker and therapeutic target. Cancer Sci. 2018; 109: 1292–9. [Pubmed] [Google Scholar]
Shen Y, Chen CS, Ichikawa H, Goldberg GS. SRC induces podoplanin expression to promote cell migration. J Biol Chem. 2010; 285: 96499656. [Pubmed] [Google Scholar]
Nose K, Saito H, Kuroki T. Isolation of a gene sequence induced later by tumorpromoting 12-O-tetradecanoylphorbol13-acetate in mouse osteoblastic cells (MC3T3-E1) and expressed constitutively in ras-transformed cells. Cell Growth Differ. 1990; 1: 511-8. [Pubmed] [Google Scholar]
Gandarillas A, Scholl FG, Benito N, Gamallo C, Quintanilla M. Induction of PA2.26, a cell-surface antigen expressed by active fibroblasts, in mouse epidermal keratinocytes during carcinogenesis. Mol Carcinog. 1997; 20: 10-8. [Pubmed] [Google Scholar]
Chatzizacharias NA, Kouraklis GP, Giaginis CT, Theocharis SE. Clinical significance of Src expression and activity in human neoplasia. Histol Histopathol. 2012;27: 677-92. [Pubmed] [Google Scholar]
Krishnan H, Goldberg GS. Contact normalization or escape from the matrix. In: Kandouz M, ed. Intercellular Communication in Cancer. Boston, MA:
Springer; 2015: 297-342.
Wicki A, Christofori G. The potential role of podoplanin in tumour invasion. Br J Cancer. 2007; 96: 1-5. [Pubmed] [Google Scholar]
Krishnan H, Retzbach EP, Ramirez MI, Liu T, Li H, Miller WT, Goldberg GS. PKA and CDK5 can phosphorylate specific serines on the intracellular domain of podoplanin (PDPN) to inhibit cell motility. Exp Cell Res. 2015; 335: 115-22. [Pubmed] [Google Scholar]
Scholl FG, Gamallo C, Vilaró S, Quintanilla M. Identification of PA2.26 antigen as a novel cell-surface mucin-type glycoprotein that induces plasma membrane extensions and increased motility in keratinocytes. J Cell Sci. 1999; 112: 4601-13. [Pubmed] [Google Scholar]
Huber GF, Fritzsche FR, Züllig L, Storz M, Graf N, Haerle SK, Jochum W, Stoeckli SJ, Moch H. Podoplanin expression correlates with sentinel lymph node metastasis in early squamous cell carcinomas of the oral cavity and oropharynx. Int J Cancer. 2011; 129: 1404-9. [Pubmed] [Google Scholar]
Ochoa-Alvarez JA, Krishnan H, Pastorino JG, Nevel E, Kephart D, Lee JJ, Retzbach EP, Shen Y, Fatahzadeh M, Baredes S, Kalyoussef E, Honma M, Adelson ME, Kaneko MK, Kato Y, Young MA, DelucaRapone L, Shienbaum AJ, Yin K, Jensen LD, Goldberg GS. Antibody and lectin target podoplanin to inhibit oral squamous carcinoma cell migration and viability by distinct mechanisms. Oncotarget. 2015; 6: 9045-60. [Pubmed] [Google Scholar]
Swain N, Kumar SV, Routray S, Pathak J, Patel S. Podoplanin–A novel marker in oral carcinogenesis. Tumour Biol. 2014; 35: 8407-13. [Pubmed] [Google Scholar]
Kan S, Konishi E, Arita T, Ikemoto C, Takenaka H, Yanagisawa A, Katoh N, Asai J. Podoplanin expression in cancer-associated fibroblasts predicts
aggressive behavior in melanoma. J Cutan Pathol. 2014; 41: 561-7. [Pubmed] [Google Scholar]
Cho Z, Konishi E, Kanemaru M, Isohisa T, Arita T, Kawai M, Tsutsumi M, Mizutani H, Takenaka H, Ozawa T, Tsuruta D, Katoh N, Asai J. Podoplanin
expression in peritumoral keratinocytes predicts aggressive behavior in extramammary Paget's disease. J Dermatol Sci. 2017; 87: 29- 35. [Pubmed] [Google Scholar]
Wicki A, Christofori G. The potential role of podoplanin in tumour invasion. Br J Cancer. 2007; 96: 1–5. [Pubmed] [Google Scholar]
Martín-Villar E, Megías D, Castel S, Yurrita MM, Vilaró S, Quintanilla M. Podoplanin binds ERM proteins to activate RhoA and promote epithelialmesenchymal transition. J Cell Sci. 2006; 119: 4541-53. [Pubmed] [Google Scholar]
Mishima K, Kato Y, Kaneko MK, Nishikawa R, Hirose T, Matsutani M. Increased expression of podoplanin in malignant astrocytic tumors as a novel
molecular marker of malignant progression. Acta Neuropathol. 2006; 111: 483-8. [Pubmed] [Google Scholar]
Shibahara J, Kashima T, Kikuchi Y, Kunita A, Fukayama M. Podoplanin is expressed in subsets of tumors of the central nervous system. Virchows
Arch. 2006; 448: 493-9. [Pubmed] [Google Scholar]
Dumoff KL, Chu C, Xu X, Pasha T, Zhang PJ, Acs G. Low D2-40 immunoreactivity correlates with lymphatic invasion and nodal metastasis in early-stage squamous cell carcinoma of the uterine cervix. Mod Pathol. 2005; 18: 97-104. [Pubmed] [Google Scholar]
Schacht V, Dadras SS, Johnson LA, Jackson DG, Hong YK, Detmar M. Up-regulation of the lymphatic marker podoplanin, a mucin-type transmembrane
glycoprotein, in human squamous cell carcinomas and germ cell tumors. Am J Pathol. 2005; 166: 913-21. [Pubmed] [Google Scholar]
Ordóñez NG. The diagnostic utility of immunohistochemistry in distinguishing between epithelioid mesotheliomas and squamous carcinomas of the lung: a comparative study. Mod Pathol. 2006; 19: 417-28. [Pubmed] [Google Scholar]
de Vicente JC, Rodrigo JP, RodriguezSantamarta T, Lequerica-Fernández P, Allonca E, García-Pedrero JM. Podoplanin expression in oral leukoplakia:
tumorigenic role. Oral Oncol. 2013; 49: 598-603. [Pubmed] [Google Scholar]
Kawaguchi H, El-Naggar AK, Papadimitrakopoulou V, Ren H, Fan YH, Feng L, Lee JJ, Kim E, Hong WK, Lippman SM, Mao L. Podoplanin: a novel marker
for oral cancer risk in patients with oral premalignancy. J Clin Oncol. 2008; 26: 354-60. [Pubmed] [Google Scholar]
Shi P, Liu W, Zhou ZT, He QB, Jiang WW. Podoplanin and ABCG2: malignant transformation risk markers for oral lichen planus. Cancer Epidemiol
Biomarkers Prev. 2010; 19: 844-9. [Pubmed] [Google Scholar]
Saintigny P, El-Naggar AK, Papadimitrakopoulou V, Ren H, Fan YH, Feng L, Lee JJ, Kim ES, Hong WK, Lippman SM, Mao L. DeltaNp63 overexpression,
alone and in combination with other biomarkers, predicts the development of oral cancer in patients with leukoplakia. Clin Cancer Res. 2009; 15: 6284-91. [Pubmed] [Google Scholar]
Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002; 2: 442-54. [Pubmed] [Google Scholar]
Lee LK, Gan VC, Lee VJ, Tan AS, Leo YS, Lye DC. Clinical relevance and discriminatory value of elevated liver aminotransferase
levels for dengue severity. PLoS Negl Trop Dis. 2012; 6: e1676. [Pubmed] [Google Scholar]
Suzuki H, Kaneko MK, Kato Y. Roles of Podoplanin in Malignant Progression of Tumor. Cells. 2022; 11: 575. [Pubmed] [Google Scholar]
Sayama Y, Sano M, Kaneko MK, Kato Y. Epitope Analysis of an Anti-Whale Podoplanin Monoclonal Antibody, PMab237, Using Flow Cytometry. Monoclon
Antib Immunodiagn Immunother. 2020; 39: 17-22. [Pubmed] [Google Scholar]
Sayama Y, Sano M, Asano T, Furusawa Y, Takei J, Nakamura T, Yanaka M, Okamoto S, Handa S, Komatsu Y, Nakamura Y, Yanagawa M, Kaneko MK, Kato Y. Epitope Mapping of PMab-241, a Lymphatic Endothelial Cell-Specific Anti-Bear Podoplanin Monoclonal Antibody. Monoclon Antib Immunodiagn
Immunother. 2020; 39: 77-81. [Pubmed] [Google Scholar]
Kato Y, Sano M, Asano T, Sayama Y, Kaneko MK. Thr80 of Sheep Podoplanin Is a Critical Epitope of the Antisheep Podoplanin Monoclonal Antibody: PMab256. Monoclon Antib Immunodiagn Immunother. 2020; 39: 95-100. [Pubmed] [Google Scholar]
Suzuki J, Aokage K, Neri S, Sakai T, Hashimoto H, Su Y, Yamazaki S, Nakamura H, Tane K, Miyoshi T, Sugano M, Kojima M, Fujii S, Kuwata T, Ochiai A, Tsuboi M, Ishii G. Relationship between podoplaninexpressing cancer-associated fibroblasts and the immune microenvironment of early lung squamous cell carcinoma. Lung Cancer. 2021; 153: 1-10. [Pubmed] [Google Scholar]
Kuwata T, Yoneda K, Mori M, Kanayama M, Kuroda K, Kaneko MK, Kato Y, Tanaka F. Detection of Circulating Tumor Cells (CTCs) in Malignant Pleural
Mesothelioma (MPM) with the "Universal" CTC-Chip and An AntiPodoplanin Antibody NZ-1.2. Cells. 2020; 9: 888. [Pubmed] [Google Scholar]
Nishinaga Y, Sato K, Yasui H, Taki S, Takahashi K, Shimizu M, Endo R, Koike C, Kuramoto N, Nakamura S, Fukui T, Yukawa H, Baba Y, K Kaneko M, ChenYoshikawa TF, Kobayashi H, Kato Y, Hasegawa Y. Targeted Phototherapy for Malignant Pleural Mesothelioma: NearInfrared Photoimmunotherapy Targeting
Podoplanin. Cells. 2020; 9: 1019. [Pubmed] [Google Scholar]
Kanayama M, Oyama R, Mori M, Taira A, Shinohara S, Kuwata T, Takenaka M, Yoneda K, Kuroda K, Ohnaga T, Kato Y, Tanaka F. Novel circulating tumor celldetection chip combining conventional podoplanin and EGFR antibodies for all histological malignant pleural mesothelioma. Oncol Lett. 2021; 22:
[Pubmed] [Google Scholar]
de Winde CM, George SL, CrosasMolist E, Hari-Gupta Y, Arp AB, Benjamin AC, Millward LJ, Makris S, Carver A, Imperatore V, Martínez VG, Sanz-Moreno V, Acton SE. Podoplanin drives dedifferentiation and amoeboid invasion of melanoma. iScience. 2021; 24: 102976. [Pubmed] [Google Scholar]
Miyashita T, Neri S, Hashimoto H, Akutsu A, Sugano M, Fujii S, Ochiai A, Ishii G. Fibroblasts-dependent invasion of podoplanin-positive cancer stem cells in squamous cell carcinoma. J Cell Physiol. 2020; 235: 7251-7260. [Pubmed] [Google Scholar]
Kato Y, Ito Y, Ohishi T, Kawada M, Nakamura T, Sayama Y, Sano M, Asano T, Yanaka M, Okamoto S, Handa S, Komatsu Y, Takei J, Kaneko MK. Antibody-Drug Conjugates Using Mouse-Canine Chimeric Anti-Dog Podoplanin Antibody Exerts Antitumor Activity in a Mouse Xenograft Model. Monoclon Antib Immunodiagn Immunother. 2020; 39: 37-44. [Pubmed] [Google Scholar]
Maekawa N, Konnai S, Nishimura M, Kagawa Y, Takagi S, Hosoya K, Ohta H, Kim S, Okagawa T, Izumi Y, Deguchi T, Kato Y, Yamamoto S, Yamamoto K,
Toda M, Nakajima C, Suzuki Y, Murata S, Ohashi K. PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PDL1 antibody in dogs with pulmonary metastatic oral malignant melanoma. NPJ Precis Oncol. 2021; 5:10. [Pubmed] [Google Scholar]
Kobayashi, H.; Furusawa, A.; Rosenberg, A.; Choyke, P.L. Nearinfrared photoimmunotherapy of cancer: A new approach that kills cancer cells and enhances anti-cancer host immunity. Int. Immunol. 2021, 33, 7–15. [Pubmed] [Google Scholar] 50. Sudo, H.; Tsuji, A.B.; Sugyo, A.; Kaneko, M.K.; Kato, Y.; Nagatsu, K.; Suzuki, H.; Higashi, T. Preclinical Evaluation of Podoplanin-Targeted AlphaRadioimmunotherapy with the Novel Antibody NZ-16 for Malignant Mesothelioma. Cells 2021, 10, 2503. [Pubmed] [Google Scholar]
Depósito Legal: ppi201102ME3935 - ISSN: 2477-9369.
Copyright ©2012 ULA Todos los derechos reservados
Todos los documentos publicados en esta revista se distribuyen bajo una
Licencia Creative Commons Atribución -No Comercial- Compartir Igual 4.0 Internacional.
Por lo que el envío, procesamiento y publicación de artículos en la revista es totalmente gratuito.